DENVER, Colo., Nov 6, 2023 (www.247marketnews.com)- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) presented, after Friday’s market close, initial monotherapy dose-escalation portion data from its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaker poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data suggests a potential best-in-class safety and pharmacokinetic profile among VISTA blocking antibodies and the potential to overcome long-standing pharmacological challenges encountered by first generation approaches to blocking VISTA.
Sensei Biotherapeutics is trading at $0.7943, up 0.1043 (+15.12), on 307.9K premarket shares traded.
Its 52-week range is $0.51 to $1.926. Its next resistance point is $0.87, but the volume needs to increase for it to make a meaningful move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.